News
![Non-alcoholic_fatty_liver_disease1](https://pharmaphorum.com/wp-content/uploads/2020/05/Non-alcoholic_fatty_liver_disease1.jpg)
Genfit’s NASH hopes are dashed by phase 3 trial fail
Genfit has seen almost two-thirds of the value wiped off its shares after its much-anticipated pivotal trial of non-alcoholic steatohepatitis (NASH) drug elafibranor turned out